Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological Sciences (CITAB), University of Minho, Braga, P...
Guardado en:
Autores principales: | Marslin G, Revina AM, Khandelwal VKM, Balakumar K, Prakash J, Franklin G, Sheeba CJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca3682a6eef24e259b3fb696eeced387 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Periorbital edema secondary to imatinib mesylate
por: Collin M McClelland, et al.
Publicado: (2010) -
In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery
por: Xu H, et al.
Publicado: (2021) -
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
por: Clara I Aceves-Luquero, et al.
Publicado: (2009) -
Cordycepin Nanoencapsulated in Poly(Lactic-Co-Glycolic Acid) Exhibits Better Cytotoxicity and Lower Hemotoxicity Than Free Drug
por: Marslin G, et al.
Publicado: (2020) -
Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
por: Jennifer S Carew, et al.
Publicado: (2008)